Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nilotinib in pediatric Ph+ chronic myelogenous leukemia (phase II, Japan)
jRCT2080222210Phase 2Completed
- Sponsor
- Novartis
- Start
- Sep 2013
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of nilotinib in chronic myelogenous leukemia (CML), sponsored by Novartis. Started Sep 2013; status: completed.
02
Drugs
nilotinib
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on jRCT2080222210.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222210.